In plain English
Amgen Inc. develops and sells biologic medicines for cancer, inflammation, and other conditions, targeting patients with serious diseases…
Equity · NASDAQ · USD
AMGN
Amgen Inc
$408.27
Today
−$1.97-0.48%
vs previous close
Quote
- Open
- $410.12
- High
- $415.76
- Low
- $407.05
- Prev close
- $410.24
- Sector
- Healthcare
- Industry
- Biotechnology
- Size
- Large-cap
- Market cap
- $221.8B
- Shares out
- 539.7M
- Country
- US
- IPO
- Jun 17, 1983
- Exchange
- NASDAQ
- Website
- amgen.com
- Next earnings
- 2026-11-02 · After close · EPS est. 5.90
Themes
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What AMGN is
Plain English context — why the name shows up in the news, and what to watch next. Not a tip.
Latest on this name
Insights & deeper context
12 recent cards — open any for the full deeper dive.
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data
In brief
Amgen’s Phase 3 trial hit its primary goal, but a second positive study is still needed before FDA filing.
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
In brief
Pyxis Oncology’s stock climbed after naming a CEO with a strong deal‑making background and gearing up to unveil promising clinical data, sparking short‑term upside and potential long‑term partnership opportunities.
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
In brief
Amgen’s stock plunged 9.8% after Novartis’ failed Lp(a) trial, shaking confidence in Amgen’s competing therapy.
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
In brief
Oil‑driven yield spike fuels a Fed‑rate‑hike bet, weighing on equities and amplifying biotech volatility.
What's Going On With Amgen Stock Tuesday?
In brief
Amgen’s stock slid sharply as the Novartis Phase 3 failure cast doubt on the Lp(a)‑lowering strategy that underpins Amgen’s olpasiran program.
Reported Earlier, Amgen Says Repatha Cut Death Risk By 20% In High-Risk Heart Patients
In brief
Repatha cuts death risk by 20% in high‑risk adults without prior heart events.
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
In brief
Tezspire’s Phase 3 win positions it as the first approved treatment for EoE, potentially opening a sizable new market for AstraZeneca and Amgen.
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
In brief
TEZSPIRE’s Phase III trial shows sustained, clinically meaningful benefits in EoE, supporting its future development and market potential.
Here’s How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
In brief
Over 15 years, AMGN outperformed the market, turning a $1,000 investment into over $8,000 thanks to strong compounded returns.
Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
In brief
Snowflake’s price target bump of 25% from Citizens signals a bullish outlook that could drive a near‑term rally.
Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’
In brief
Chubb, Amgen, and Toast are recommended stocks with strong earnings and guidance, indicating potential for growth and increased stock prices.
Amgen Identifies Unauthorized Activity In Third-party Cloud Environments In July 2026; Reports No Impact To Products, Operations, Or Financial Reporting From Incident; Reports Exfiltration Of Proprietary And Patient Data From Cloud Environments
In brief
Amgen identified unauthorized activity in third-party cloud environments, resulting in data exfiltration, but believes it won't have a material financial impact.
Filings & reports
SEC and filing-linked cards
No filings tagged yet
Filing-linked cards for AMGN will show up here when available.
Indexes like the S&P 500 are shown via liquid ETFs (e.g. SPY). Company profile and quotes use live market data when available.